ASSURed awareness campaign to address parental hesitancy and encourage childhood vaccine uptakE in Nigeria: a pilot randomised controlled trial
Abstract
BackgroundParental vaccine hesitancy is a prevalent global challenge, particularly in Nigeria, where many children remain zero-dose. Yet, a gap remains in testing the feasibility and acceptability of a co-produced ASSURed awareness campaign to encourage childhood vaccine uptakE (ASSURE) among parents who are not or partially up-to-date with their child’s vaccinations – representing the study’s primary aims.MethodA mixed-methods randomised controlled trial (RCT) compared ASSURE with usual intervention alone among 74 parents recruited from Delta State, Nigeria, whose children were not or partially up to date with their vaccines. At baseline, 74 participants were recruited and randomised; however, four participants dropped out after the intervention, leaving 70 who completed the assessment at the end of the intervention. The ASSURE intervention is a 3-min media campaign designed to increase awareness of the risks of vaccine hesitancy, highlight the benefits of childhood vaccination, reduce vaccine-related anxiety, and provide information on accessing immunisation services. The primary outcome was feasibility, measured by participant recruitment and retention rates, while the intervention’s acceptability was measured by the Service Satisfaction Scale (SSS). For secondary outcomes, the study evaluated the intervention’s potential efficacy in addressing vaccine-related anxiety, measured using the Generalised Anxiety Disorder (GAD-7) scale and conspiracy beliefs about vaccines limiting uptake, measured using the World Health Organization-Childhood Vaccine Hesitancy Scale (WHO-CVHS). Outcomes were assessed at baseline and the End of the Intervention (EOI) using a survey-questionnaire.ResultsThe Experimental Group (EG) (n = 36) reported a high participant recruitment and retention rate of 97% at the end of the intervention, compared with 92% in the control group (n = 34). In addition, EG reported higher satisfaction with SSS (75%) than the control group, where 26% reported satisfaction and 15% were unsure. Regarding the secondary outcomes, for GAD-7 scores, EG showed a potential reduction in anxiety from baseline to EOI compared to the control group, with differences at the end of intervention indicating −9.16 (−11.99 to −6.32) (p < 0.001) compared to the baseline showing −1.675 (−4.09 to 0.748) (p > 0.172). Regarding WHO-CVHS, the experimental group demonstrated some reductions in hesitancy from baseline to EOI compared with the control group, with reductions of −18.70 (−23.39 to −14.00) (p < 0.001) at the end of intervention compared to −2.675 (−5.38 to 0.033) (p > 0.053) at baseline.ConclusionThe ASSURE intervention is feasible, acceptable and appropriate for addressing childhood vaccine hesitancy in Nigeria. Further adequately powered RCTs evaluating the intervention’s effectiveness and cost-effectiveness are recommended.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT07510230?term=NCT07510230&viewType=Card&rank=1.
Related
- Factors influencing childhood vaccine hesitancy and interventions for parents and caregivers from ethnic minority backgrounds in the United Kingdom to encourage uptake: a systematic review
- Enhancing physical activity in early childhood for 3–5-year-old children born very preterm: protocol for an Australian randomised controlled trial of Active-Prem
- PRE-Pregnancy Weight Loss and the Reducing Effect on CHILDhood Overweight (PREPARE CHILD): clinical trial protocol for a randomised controlled trial
- Vaccine hesitancy and misinformation in Pakistan: Challenges to childhood immunisation
- Parental perceptions, information sources, and practices related to childhood immunization and HPV vaccine awareness in Saudi Arabia: an observational study
BibTeX
@article{ike2026assured,
title = {{ASSURed awareness campaign to address parental hesitancy and encourage childhood vaccine uptakE in Nigeria: a pilot randomised controlled trial}},
author = {Tarela Juliet Ike and Dung Ezekiel Jidong and Callistar Kidochukwu Obi and Maureen Iru Ntaji and Mulugeta Tamire and Marekegn Habtamu and Mieyebi Lawrence Ike and Evangelyn Ebi Ayobi and Peremi Richmond Ike and Rukevwe Francis Doghor and Rakhshi Memon and Christopher Francis and Kelvin Odeyovwi Ayobi and Aboneh Solomon Sime and Nusrat Husain},
journal = {Frontiers in Public Health},
year = {2026},
month = nov,
doi = {10.3389/fpubh.2026.1928765},
url = {https://www.frontiersin.org/articles/10.3389/fpubh.2026.1928765},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - ASSURed awareness campaign to address parental hesitancy and encourage childhood vaccine uptakE in Nigeria: a pilot randomised controlled trial
AU - Tarela Juliet Ike
AU - Dung Ezekiel Jidong
AU - Callistar Kidochukwu Obi
AU - Maureen Iru Ntaji
AU - Mulugeta Tamire
AU - Marekegn Habtamu
AU - Mieyebi Lawrence Ike
AU - Evangelyn Ebi Ayobi
AU - Peremi Richmond Ike
AU - Rukevwe Francis Doghor
AU - Rakhshi Memon
AU - Christopher Francis
AU - Kelvin Odeyovwi Ayobi
AU - Aboneh Solomon Sime
AU - Nusrat Husain
PY - 2026
DA - 2026/11/04
JO - Frontiers in Public Health
DO - 10.3389/fpubh.2026.1928765
UR - https://www.frontiersin.org/articles/10.3389/fpubh.2026.1928765
AB - BackgroundParental vaccine hesitancy is a prevalent global challenge, particularly in Nigeria, where many children remain zero-dose. Yet, a gap remains in testing the feasibility and acceptability of a co-produced ASSURed awareness campaign to encourage childhood vaccine uptakE (ASSURE) among parents who are not or partially up-to-date with their child’s vaccinations – representing the study’s primary aims.MethodA mixed-methods randomised controlled trial (RCT) compared ASSURE with usual intervention alone among 74 parents recruited from Delta State, Nigeria, whose children were not or partially up to date with their vaccines. At baseline, 74 participants were recruited and randomised; however, four participants dropped out after the intervention, leaving 70 who completed the assessment at the end of the intervention. The ASSURE intervention is a 3-min media campaign designed to increase awareness of the risks of vaccine hesitancy, highlight the benefits of childhood vaccination, reduce vaccine-related anxiety, and provide information on accessing immunisation services. The primary outcome was feasibility, measured by participant recruitment and retention rates, while the intervention’s acceptability was measured by the Service Satisfaction Scale (SSS). For secondary outcomes, the study evaluated the intervention’s potential efficacy in addressing vaccine-related anxiety, measured using the Generalised Anxiety Disorder (GAD-7) scale and conspiracy beliefs about vaccines limiting uptake, measured using the World Health Organization-Childhood Vaccine Hesitancy Scale (WHO-CVHS). Outcomes were assessed at baseline and the End of the Intervention (EOI) using a survey-questionnaire.ResultsThe Experimental Group (EG) (n = 36) reported a high participant recruitment and retention rate of 97% at the end of the intervention, compared with 92% in the control group (n = 34). In addition, EG reported higher satisfaction with SSS (75%) than the control group, where 26% reported satisfaction and 15% were unsure. Regarding the secondary outcomes, for GAD-7 scores, EG showed a potential reduction in anxiety from baseline to EOI compared to the control group, with differences at the end of intervention indicating −9.16 (−11.99 to −6.32) (p < 0.001) compared to the baseline showing −1.675 (−4.09 to 0.748) (p > 0.172). Regarding WHO-CVHS, the experimental group demonstrated some reductions in hesitancy from baseline to EOI compared with the control group, with reductions of −18.70 (−23.39 to −14.00) (p < 0.001) at the end of intervention compared to −2.675 (−5.38 to 0.033) (p > 0.053) at baseline.ConclusionThe ASSURE intervention is feasible, acceptable and appropriate for addressing childhood vaccine hesitancy in Nigeria. Further adequately powered RCTs evaluating the intervention’s effectiveness and cost-effectiveness are recommended.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT07510230?term=NCT07510230&viewType=Card&rank=1.
SN - 2296-2565
ER -